Intra Cellular Therapies, Inc. - Understand $itci stock

$ITCI Market Cap: $9.112 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$613.7M

TTM

Gross Margin

92.33%

TTM

Net Earnings

-$86.37M

TTM

Current Assets

$1.272B

Q3 2024

Current Liabilities

$166.1M

Q3 2024

Current Ratio

765.58%

Q3 2024

Total Assets

$1.324B

Q3 2024

Total Liabilities

$179.6M

Q3 2024

Book Value

$1.145B

Q3 2024

Cash

$464.3M

Q3 2024

P/E

-105.5

Nov 29, 2024 EST

Free Cash Flow

-$28.79M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$464.4M	$250.3M	$83.80M	$22.81M	$60.00K	$0.00	$245.8K	$330.7K	$91.36K	$577.3K	$2.737M	$3.118M	$23.36M
YoY Change	85.51%	198.69%	267.4%	37916.67%		-100.0%	-25.66%	261.96%	-84.17%	-78.91%	-12.22%	-86.65%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$464.4M	$250.3M	$83.80M	$22.81M	$60.00K	$0.00	$245.8K	$330.7K	$91.36K	$577.3K	$2.737M	$3.118M	$23.36M
Cost Of Revenue	$33.75M	$20.44M	$8.035M	$1.900M
Gross Profit	$430.6M	$229.9M	$75.77M	$20.92M
Gross Profit Margin	92.73%	91.83%	90.41%	91.71%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Selling, General & Admin	$409.9M	$358.8M	$272.6M	$186.4M	$64.95M	$30.10M	$23.67M	$24.76M	$18.19M	$10.34M	$5.980M	$4.030M	$4.610M
YoY Change	14.24%	31.61%	46.28%	186.93%	115.78%	27.17%	-4.4%	36.12%	75.92%	72.91%	48.39%	-12.58%
% of Gross Profit	95.18%	156.08%	359.8%	890.82%
Research & Development	$180.1M	$134.7M	$88.85M	$65.78M	$89.12M	$132.2M	$79.42M	$93.83M	$87.72M	$21.23M	$23.03M	$15.49M	$7.650M
YoY Change	33.72%	51.63%	35.06%	-26.19%	-32.57%	66.42%	-15.36%	6.97%	313.25%	-7.82%	48.69%	102.44%
% of Gross Profit	41.83%	58.6%	117.26%	314.44%
Depreciation & Amortization	$528.0K	$700.0K	$533.4K	$530.0K	$480.0K	$368.7K	$213.9K	$196.9K	$139.6K	$25.48K	$23.25K	$47.75K	$190.0K
YoY Change	-24.57%	31.24%	0.63%	10.42%	30.2%	72.38%	8.64%	41.0%	447.96%	9.6%	-51.31%	-74.87%
% of Gross Profit	0.12%	0.3%	0.7%	2.53%
Operating Expenses	$623.8M	$513.9M	$361.5M	$252.1M	$154.1M	$162.3M	$103.1M	$118.6M	$105.9M	$31.56M	$23.03M	$15.49M	$12.27M
YoY Change	21.37%	42.19%	43.36%	63.65%	-5.05%	57.41%	-13.07%	11.98%	235.53%	37.07%	48.69%	26.21%
Operating Profit	-$159.4M	-$263.6M	-$285.7M	-$231.2M		-$162.3M	-$102.8M	-$118.3M	-$105.8M	-$30.99M	-$26.27M	-$16.40M
YoY Change	-39.54%	-7.72%	23.56%			57.79%	-13.04%	11.76%	241.48%	17.97%	60.13%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Interest Expense	$20.34M	$7.376M	$1.568M	$4.240M	$6.290M	$7.140M	$4.010M	$36.78K	$1.020M	$7.073K	$613.0K	$193.5K	$60.00K
YoY Change	175.8%	370.38%	-63.02%	-32.59%	-11.9%	78.05%	10802.37%	-96.39%	14321.04%	-98.85%	216.78%	222.5%
% of Operating Profit
Other Income/Expense, Net
YoY Change

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Pretax Income	-$139.0M	-$256.3M	-$284.1M	-$227.0M	-$147.7M	-$155.1M	-$98.83M	-$115.4M	-$104.8M	-$30.69M	-$26.85M	-$16.56M	$11.16M
YoY Change	-45.74%	-9.81%	25.17%	53.66%	-4.77%	56.96%	-14.33%	10.09%	241.45%	14.3%	62.14%	-248.39%
Income Tax	$636.0K	$6.000K	$5.630K	$10.00K	$0.00	$1.600K	-$1.061M	$1.066M	$1.600K	$1.600K	$18.00K	$32.92K	$60.00K
% Of Pretax Income													0.54%
Net Earnings	-$139.7M	-$256.3M	-$284.1M	-$227.0M	-$147.7M	-$155.1M	-$97.77M	-$116.4M	-$104.8M	-$30.69M	-$26.87M	-$16.59M	$11.09M
YoY Change	-45.49%	-9.81%	25.16%	53.68%	-4.78%	58.66%	-16.02%	11.1%	241.44%	14.23%	61.95%	-249.6%
Net Earnings / Revenue	-30.08%	-102.37%	-339.04%	-995.22%	-246200.0%		-39771.64%	-35205.79%	-114698.5%	-5316.37%	-981.67%	-532.1%	47.47%
Basic Earnings Per Share	-$1.46	-$2.72	-$3.50	-$3.23
Diluted Earnings Per Share	-$1.46	-$2.72	-$3.497M	-$3.226M	-$2.677M	-$2.835M	-$2.117M	-$2.693M	-$2.905M	-$1.071M	-$1.557M	-$2.957M	$840.8K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Cash & Short-Term Investments	$497.9M	$591.9M	$412.3M	$657.4M	$224.0M	$347.5M	$464.3M	$384.1M	$475.2M	$129.6M	$37.20M	$19.10M	$22.90M
YoY Change	-15.87%	43.55%	-37.28%	193.48%	-35.54%	-25.16%	20.88%	-19.17%	266.67%	248.39%	94.76%	-16.59%
Cash & Equivalents	$147.8M	$148.6M	$92.36M	$60.00M	$107.6M	$54.90M	$37.80M	$48.60M	$47.20M	$61.30M	$35.20M	$15.60M	$13.70M
Short-Term Investments	$350.2M	$443.3M	$320.0M	$597.4M	$116.4M	$292.6M	$426.5M	$335.5M	$428.0M	$68.30M	$2.000M	$3.500M	$9.200M
Other Short-Term Assets	$44.19M	$46.94M	$26.84M	$15.60M	$6.300M	$7.900M	$4.900M	$4.000M	$8.000M	$1.300M	$800.0K	$200.0K	$100.0K
YoY Change	-5.86%	74.88%	72.07%	147.62%	-20.25%	61.22%	22.5%	-50.0%	515.38%	62.5%	300.0%	100.0%
Inventory	$11.65M	$23.92M	$7.948M	$7.100M
Prepaid Expenses
Receivables	$114.0M	$75.19M	$20.16M	$10.80M			$0.00	$100.0K	$0.00	$100.0K	$300.0K	$300.0K	$300.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00			$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$667.8M	$738.0M	$467.3M	$690.9M	$230.3M	$355.4M	$469.2M	$388.2M	$483.3M	$131.0M	$38.20M	$19.60M	$23.40M
YoY Change	-9.51%	57.93%	-32.37%	200.0%	-35.2%	-24.25%	20.87%	-19.68%	268.93%	242.93%	94.9%	-16.24%
Property, Plant & Equipment	$14.58M	$16.74M	$22.56M	$26.30M	$20.50M	$1.200M	$1.100M	$600.0K	$800.0K	$100.0K	$100.0K	$100.0K	$100.0K
YoY Change	-12.88%	-25.8%	-14.24%	28.29%	1608.33%	9.09%	83.33%	-25.0%	700.0%	0.0%	0.0%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$45.91M	$86.00K	$86.08K	$100.0K	$400.0K	$600.0K	$1.100M	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$200.0K
YoY Change	53288.37%	-0.09%	-13.92%	-75.0%	-33.33%	-45.45%	1000.0%	0.0%	0.0%	0.0%	0.0%	-50.0%
Total Long-Term Assets	$60.50M	$16.82M	$22.64M	$26.40M	$20.90M	$1.800M	$2.300M	$700.0K	$800.0K	$100.0K	$200.0K	$200.0K	$200.0K
YoY Change	259.6%	-25.7%	-14.24%	26.32%	1061.11%	-21.74%	228.57%	-12.5%	700.0%	-50.0%	0.0%	0.0%
Total Assets	$728.3M	$754.8M	$489.9M	$717.3M	$251.2M	$357.2M	$471.5M	$388.9M	$484.1M	$131.1M	$38.40M	$19.80M	$23.60M
YoY Change
Accounts Payable	$11.45M	$10.40M	$8.691M	$5.500M	$7.400M	$14.00M	$6.200M	$3.800M	$1.600M	$2.100M	$3.400M	$0.00	$600.0K
YoY Change	10.17%	19.6%	58.02%	-25.68%	-47.14%	125.81%	63.16%	137.5%	-23.81%	-38.24%		-100.0%
Accrued Expenses	$112.1M	$72.84M	$44.67M	$31.40M	$28.80M	$22.30M	$8.000M	$6.800M	$4.600M	$8.500M	$3.400M	$1.100M	$1.800M
YoY Change	53.89%	63.08%	42.25%	9.03%	29.15%	178.75%	17.65%	47.83%	-45.88%	150.0%	209.09%	-38.89%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$123.5M	$83.24M	$53.36M	$36.90M	$36.20M	$36.30M	$14.20M	$10.50M	$6.300M	$10.60M	$6.800M	$2.800M	$4.000M
YoY Change	48.43%	56.0%	44.6%	1.93%	-0.28%	155.63%	35.24%	66.67%	-40.57%	55.88%	142.86%	-30.0%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$13.33M	$15.47M	$18.67M	$23.60M	$20.00M	$3.200M	$2.800M	$2.900M	$1.600M				$1.700M
YoY Change	-13.88%	-17.14%	-20.87%	18.0%	525.0%	14.29%	-3.45%	81.25%
Total Long-Term Liabilities	$13.33M	$15.47M	$18.67M	$23.60M	$20.00M	$3.200M	$2.800M	$2.900M	$1.600M	$0.00	$0.00	$0.00	$1.700M
YoY Change	-13.88%	-17.14%	-20.87%	18.0%	525.0%	14.29%	-3.45%	81.25%				-100.0%
Total Liabilities	$136.9M	$98.71M	$72.03M	$60.50M	$56.20M	$39.50M	$17.00M	$13.40M	$7.900M	$10.60M	$6.800M	$2.800M	$5.700M
YoY Change	38.66%	37.04%	19.06%	7.65%	42.28%	132.35%	26.87%	69.62%	-25.47%	55.88%	142.86%	-50.88%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	95.88M shares	94.05M	81.25M	70.36M
Diluted Shares Outstanding	95.88M shares	94.05M	81.25M	70.36M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $9.1122 Billion

About Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 610 full-time employees. The company went IPO on 2014-01-31. The firm leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.

Industry: Pharmaceutical Preparations Peers: Catalent, Inc. CORCEPT THERAPEUTICS INC Elanco Animal Health Inc Harmony Biosciences Holdings, Inc. JOHNSON & JOHNSON Organon & Co. Prestige Consumer Healthcare Inc. Royalty Pharma plc Viatris Inc